163 related articles for article (PubMed ID: 35260794)
1. Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis.
David R; Buckby A; Kahokehr AA; Lee J; Watson DI; Leung J; O'Callaghan ME
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):8-15. PubMed ID: 35260794
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
[TBL] [Abstract][Full Text] [Related]
4. Late Genitourinary Toxicity Outcomes in 300 Prostate Cancer Patients Treated With Dose-escalated Image-guided Intensity-modulated Radiotherapy.
Byrne K; Hruby G; Kneebone A; Whalley D; Guo L; McCloud P; Eade T
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):617-625. PubMed ID: 28416260
[TBL] [Abstract][Full Text] [Related]
5. External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
Devisetty K; Zorn KC; Katz MH; Jani AB; Liauw SL
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1060-5. PubMed ID: 20045267
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
7. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
9. Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer.
Ghanem AI; Elsaid AA; Elshaikh MA; Khedr GA
Asian Pac J Cancer Prev; 2021 Jan; 22(1):61-68. PubMed ID: 33507680
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial.
Katayama S; Striecker T; Kessel K; Sterzing F; Habl G; Edler L; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):926-33. PubMed ID: 25216858
[TBL] [Abstract][Full Text] [Related]
12. Rectal and Urethro-Vesical Subregions for Toxicity Prediction After Prostate Cancer Radiation Therapy: Validation of Voxel-Based Models in an Independent Population.
Mylona E; Ebert M; Kennedy A; Joseph D; Denham J; Steigler A; Supiot S; Acosta O; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1189-1195. PubMed ID: 32673785
[TBL] [Abstract][Full Text] [Related]
13. Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.
Ghadjar P; Jackson A; Spratt DE; Oh JH; Munck af Rosenschöld P; Kollmeier M; Yorke E; Hunt M; Deasy JO; Zelefsky MJ
Eur Urol; 2013 Dec; 64(6):931-8. PubMed ID: 23522772
[TBL] [Abstract][Full Text] [Related]
14. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
15. The Fraction Size Sensitivity of Late Genitourinary Toxicity: Analysis of Alpha/Beta (α/β) Ratios in the CHHiP Trial.
Brand DH; Brüningk SC; Wilkins A; Naismith O; Gao A; Syndikus I; Dearnaley DP; van As N; Hall E; Gulliford S; Tree AC;
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):327-336. PubMed ID: 35985457
[TBL] [Abstract][Full Text] [Related]
16. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.
Buckstein M; Carpenter TJ; Stone NN; Stock RG
Urology; 2013 Feb; 81(2):364-8. PubMed ID: 23374803
[TBL] [Abstract][Full Text] [Related]
18. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
[TBL] [Abstract][Full Text] [Related]
19. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
